In the present study, we investigated whether GDF15 levels can be a predictive marker in patients with NSCLC treated with PD-1/PD-L1 inhibitors and identified the association between circulating GDF15 levels and immune cell populations of peripheral blood mononuclear cells (PBMCs). Here, GDF15 is linked to non-small cell lung carcinoma.